Skip to main navigation Skip to search Skip to main content

Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ‰2 Years of Follow-Up

  • Thomas Powles
  • , Se Hoon Park
  • , Claudia Caserta
  • , Begoña P. Valderrama
  • , Howard Gurney
  • , Anders Ullén
  • , Yohann Loriot
  • , Srikala S. Sridhar
  • , Cora N. Sternberg
  • , Joaquim Bellmunt
  • , Jeanny B. Aragon-Ching
  • , Jing Wang
  • , Bo Huang
  • , Robert J. Laliberte
  • , Alessandra Di Pietro
  • , Petros Grivas
  • Queen Mary University of London
  • Azienda Ospedaliera S. Maria di Terni
  • Hospital Universitario Virgen del Rocio
  • Macquarie University
  • Karolinska Institutet
  • Gustave Roussy
  • Princess Margaret Cancer Centre
  • Cornell University
  • Harvard University
  • Inova Schar Cancer Institute
  • Pfizer
  • University of Washington

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ‰2 Years of Follow-Up'. Together they form a unique fingerprint.
Sort by

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology